In a patient with multiple myeloma, is lenalidomide administered intravenously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, lenalidomide is NOT administered intravenously

Lenalidomide is administered orally as a capsule, not intravenously 1. This is clearly established in the FDA drug labeling, which describes lenalidomide as an oral medication with absorption occurring through the gastrointestinal tract, with maximum plasma concentrations occurring between 0.5 and 6 hours post-dose 1.

Route of Administration

The FDA labeling explicitly states that lenalidomide is administered orally and can be taken with or without food 1. The drug comes in capsule form at various strengths (5 mg, 10 mg, 15 mg, 20 mg, and 25 mg).

Clinical Context in Multiple Myeloma

In multiple myeloma treatment regimens, lenalidomide is consistently administered orally:

  • Standard dosing: 25 mg orally on days 1-21 of a 28-day cycle when combined with dexamethasone 2
  • Maintenance therapy: 10-25 mg orally daily (typically starting at 10 mg for the first three cycles, then adjusted to best tolerated dose up to 15 mg) 2
  • In combination regimens: When used with carfilzomib (which IS given intravenously) and dexamethasone, lenalidomide remains oral at 25 mg on days 1-21 2

Common Pitfall to Avoid

Do not confuse lenalidomide with other agents in combination regimens. In regimens like VRd (bortezomib-lenalidomide-dexamethasone) or KRd (carfilzomib-lenalidomide-dexamethasone), the proteasome inhibitors (bortezomib, carfilzomib) are given intravenously or subcutaneously, while lenalidomide is always oral 3, 2.

The NCCN guidelines and ASCO guidelines consistently reference lenalidomide as an oral agent in all treatment contexts for multiple myeloma 4, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.